FierceBiotech 13 févr. 2026 Ultragenyx lays off 10% of workforce as FDA continues to stall gene therapy approval plans
FierceBiotech 13 févr. 2026 'When the markets opened, we were ready': Why biotech IPOs are back for 2026
FierceBiotech 12 févr. 2026 Icon shares plummet after CRO reveals accounting investigation, pulls 2025 guidance
FierceBiotech 12 févr. 2026 Lundbeck’s migraine prevention treatment sees ph. 2 success after trial’s earlier setback
FierceBiotech 12 févr. 2026 BridgeBio preps approval push after dwarfism drug increases children's height in phase 3
FierceBiotech 12 févr. 2026 Langer-backed biotech looks to end cancer recurrence with surgical revolution
FierceBiotech 12 févr. 2026 Agilent companion diagnostic lands FDA nod alongside Keytruda's latest cancer approval
FierceBiotech 12 févr. 2026 Seres to lay off 30% of employees, pause lead program in latest strategic shift
FierceBiotech 12 févr. 2026 Sanofi ousts Paul Hudson after ‘bumpy ride’, poaches Merck KGaA CEO to lead the French pharma
FierceBiotech 12 févr. 2026 European VCs join forces to boost flagging biotech investment in the region
FierceBiotech 12 févr. 2026 UPDATE: After Moderna's rebuke, HHS stands behind FDA decision to spurn mRNA flu filing
FierceBiotech 11 févr. 2026 ‘The only thing that saves us is data’: Allogeneic CAR-T biotechs fight for relevance as industry moves on
FierceBiotech 11 févr. 2026 Upstream posts Tezspire-like asthma efficacy in phase 2 but falls short of best-case scenario
FierceBiotech 11 févr. 2026 Madrigal pens $4.4B deal for Ribo's preclinical siRNA programs in latest Rezdiffra MASH play
FierceBiotech 11 févr. 2026 GE HealthCare debuts tech to help hospitals remotely maintain bedside ECG stations
FierceBiotech 11 févr. 2026 Moderna hit with FDA refusal-to-file letter for mRNA flu shot, issues sharp rebuke of agency's rationale